Elsevier

Ophthalmology

Volume 105, Issue 10, 1 October 1998, Pages 1902-1906
Ophthalmology

Preseptal and orbital cellulitis in childhood: A changing microbiologic spectrumHistorical image

Presented at the American Academy of Ophthalmology annual meeting, San Francisco, California, October 1997.
https://doi.org/10.1016/S0161-6420(98)91038-7Get rights and content

Abstract

Objective

The authors sought to determine whether the microbiologic spectrum of preseptal and orbital cellulitis had changed over the past decade.

Design

A retrospective chart review of all inpatient and outpatient children with an ICD-9 diagnosis of preseptal or orbital cellulitis seen at Vanderbilt University Medical Center since the introduction of the Haemophilus influenzae type-B (HiB) vaccine (1986–1996).

Main outcome measures

Blood and abscess cultures from children with preseptal and orbital cellulitis were tabulated.

Results

During this period, 70 cases of preseptal cellulitis were seen. Blood cultures were obtained in 59 cases; only 6 were positive. Five cultures grew Streptococcus species. The one positive H. influenzae culture occurred in 1987 in a child who did not receive the HiB vaccine. There have been no new patients with preseptal cellulitis and H. influenzae bacteremia at Vanderbilt for 10 years. There were ten cases of orbital cellulitis, of which blood or abscess or both were cultured in eight. Six cases had positive cultures. Four cultures grew Streptococcus species. The other two grew H. influenzae and mixed H. influenzae/gram-positive cocci.

Conclusion

The incidence of hemophilus-associated bacteremia in patients with preseptal cellulitis has decreased dramatically over the past 10 years. Streptococcus species now are the predominant cause. Orbital cellulitis due to H. influenzae may still occur, but it is much less likely. A more conservative approach to the diagnosis and management of preseptal and orbital cellulitis may be warranted.

Section snippets

Methods

This study was a retrospective chart review. All inpatients and outpatients (younger than 18 years of age) seen at Vanderbilt University Medical Center who were given an ICD-9 diagnosis corresponding to preseptal cellulitis (373.13) or orbital cellulitis (376.01) were studied. We chose patients seen during the 11-year period from 1986 to 1996, as this followed the introduction of the HiB vaccine in 1985.

We reviewed charts with specific attention paid to whether the cellulitis was orbital or

Preseptal cellulitis

There were 70 pediatric cases of preseptal cellulitis at Vanderbilt University Medical Center in the 11-year period from 1986 to 1996. Patients ranged in age from 2 months to 17 years. Although more than half of the patients had documentation that immunizations were up to date, only five had clear documentation in the chart of being immunized for Haemophilus type-B. Blood cultures were obtained in 59 (84%) of the 70 patients. These cultures were positive in only six cases (10%). Five blood

Discussion

Before the advent of the HiB vaccine, H. influenzae type-B was potentially the most feared organism in pediatric infectious disease. H. influenzae invasive disease affected nearly 1 in 200 children younger than the age of 5 years, caused 70% of bacterial meningitis, and produced devastating neurologic sequelae in approximately 3000 U.S. children each year.1 A study from this institution covering a 5-year period ending 20 years ago introduced Haemophilus sp. as the most common cause of preseptal

References (28)

  • T. Murphy et al.

    Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination

    JAMA

    (1993)
  • K.R. Powell

    Orbital and periorbital cellulitis

    Pediatr Rev

    (1995)
  • T.F. Smith et al.

    Clinical implications of preseptal (periorbital) cellulitis in childhood

    Pediatrics

    (1978)
  • Cited by (0)

    Supported in part by a grant from Research to Prevent Blindness, Inc., New York, New York.

    Neither author has any proprietary interest in any product described in this article nor in any competing product.

    View full text